Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the company will present its findings on a poster entitled, “Regulatory decisions during COVID-19: Efficient nonclinical inhalation toxicology for a clinical program,”
| ENGLEWOOD, Colo., March 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the company will present its findings on a poster entitled, “Regulatory decisions during COVID-19: Efficient nonclinical inhalation toxicology for a clinical program,” at the upcoming 23rd International Congress of the International Society for Aerosols in Medicine (ISAM).
The ISAM Congress, which aspires to bring together over 400 attendees at one of the world’s largest pulmonary drug delivery and respiratory health conferences, will be held in Boise, Idaho, May 22 to 26, 2021 with an agenda focused on: Medical Aerosols in the Age of COVID and other pandemics, acute and critical care, the developing world, pulmonary disease, inhaled viruses and viral transmission, health risks from environmental aerosols and emerging aerosol technologies. In addition to its poster presentation, number 070, the company has been invited to present at the Regulatory/Standardization issues networking group, which recently published an appeal on the urgent need to accelerate the development of inhaled therapies for COVID-19. Presentation date and time has not yet been determined. In addition, Ampio recently completed enrollment in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19. Prior to launching the trial, Ampio undertook pre-clinical research to establish the safety of its Ampion anti-inflammatory therapy in an inhaled format. Ampion, a novel biologic drug containing a blood-derived cyclized peptide and other small molecules, with the potential for treating a variety of serious and often life-threatening inflammatory conditions, had previously demonstrated its safety utilizing injection and intravenous (IV) delivery formats in other trials. The FDA identified a need to assess the no-observed adverse effect level (NOAEL) in animals with Ampion via inhalation as the intended route of administration. Ampio designed a study with FDA feedback to assess the potential local toxicity to the lung and other respiratory tissues at a range of inhalation doses. The company’s presentation will highlight the program as an example of efficient development that is responsive to both the COVID-19 pandemic and FDA requirements. The 23rd ISAM Congress is being held as a hybrid event. All posters will be posted both on the website – along with a short 2-to-5-minute oral presentation – and printed for display at the Boise Conference Center. For more details on the ISAM Congress and the timing of Ampio’s presentation, visit: www.isam.org About Ampio Pharmaceuticals Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio’s lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2035 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (“BPCIA”). Forward Looking Statements Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (“BLA”), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. Company Contacts Investor Relations Media Contact
SOURCE Ampio Pharmaceuticals, Inc. | ||
Company Codes: AMEX:AMPE |
View original content to download multimedia:
